Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Citius Pharmaceuticals Inc (NQ: CTXR ) 0.6090 -0.0315 (-4.92%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Citius Pharmaceuticals Inc < Previous 1 2 3 4 Next > Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket February 13, 2023 Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 52.5% to $0.7050 in pre-market trading after jumping over 72% on Friday. Via Benzinga Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session February 13, 2023 U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Via Benzinga Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session January 18, 2023 Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+... Via Benzinga Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm May 25, 2022 Via Benzinga Citius Pharmaceuticals (NASDAQ: CTXR) Spearheads the Global Cancer Immunotherapy Market May 07, 2022 Via Get News Exposures Product Safety Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket January 18, 2023 Gainers Siyata Mobile Inc. (NASDAQ: SYTA) rose 41.5% to $0.3255 in pre-market trading after gaining 8% on Tuesday. Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session December 26, 2022 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session December 23, 2022 Via Benzinga Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket October 17, 2022 Gainers Via Benzinga Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial April 06, 2022 Via Benzinga 11 Health Care Stocks Moving In Friday's Pre-Market Session September 23, 2022 Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million. Via Benzinga Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings September 23, 2022 Via Benzinga Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket August 11, 2022 Gainers Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday August 11, 2022 Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch! Via InvestorPlace 12 Health Care Stocks Moving In Friday's After-Market Session July 22, 2022 Gainers Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session June 07, 2022 Gainers Via Benzinga Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is Specializing in Stem Cell Therapy & Critical Cancer Care Immunotherapy May 11, 2022 Via Get News Exposures Product Safety 3 Reddit Stocks to Buy in May May 08, 2022 These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond Via InvestorPlace Citius Pharmaceuticals, Inc is helping Global Cancer Immunotherapy to reach the Market Cap of 152 Billion by 2024. May 04, 2022 Via AB Newswire Exposures Product Safety The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) May 04, 2022 Via Viz Release Exposures COVID-19 Product Safety First Patient Dosed in Citius Pharma's Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids April 26, 2022 Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced enrolment of first patient in the Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids. Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session April 06, 2022 Gainers Healthcare Triangle (NASDAQ:HCTI) stock moved upwards by 17.5% to $1.35 during Wednesday's pre-market session. The company's market cap stands at $47.6... Via Benzinga 61 Biggest Movers From Yesterday April 28, 2022 Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with... Via Benzinga The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy April 06, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session February 17, 2022 Gainers Rhythm Pharmaceuticals (NASDAQ:RYTM) stock increased by 16.4% to $7.72 during Thursday's regular session. The current volume of 639.5K shares is 152.7% of... Via Benzinga Penny Stock Watchlist - Here Are My Five Top Picks February 17, 2022 If you got into Amazon at the start of 2021, by the end of 2021 you'd have made about 73% gains. Not bad for a year. It's impressive until you consider that one of these stocks made 258% gains in the... Via Talk Markets FDA Signs Off Citius Pharma's Phase 2 Trial With Halo-Lido In Hemorrhoids February 15, 2022 The FDA has issued a Study May Proceed letter for Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Halo-Lido to treat hemorrhoids. The Company anticipates... Via Benzinga Citius Pharmaceuticals: Q1 Earnings Insights February 10, 2022 Citius Pharmaceuticals (NASDAQ:CTXR) reported its Q1 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Citius... Via Benzinga Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential September 10, 2021 Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021 November 30, 2021 Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ: Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.